Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis

@article{Feneberg2018MulticenterEO,
  title={Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis},
  author={Emily Feneberg and Patrick Oeckl and Petra Steinacker and Federico Verde and Christian Barro and Philip van Damme and Elizabeth Gray and Julian Grosskreutz and Claude Jardel and Jens Kuhle and Sonja Koerner and Foudil Lamari and Maria del Mar Amador and Benjamin Mayer and Claudia Morelli and Petra Mů{\vc}kov{\'a} and Susanne Petri and Koen Poesen and Joost Raaphorst and François Salachas and Vincenzo Silani and Beatrice Stubendorff and Martin R. Turner and Marcel M. Verbeek and Jochen H Weishaupt and Patrick Weydt and Albert Christian Ludolph and Markus Otto},
  journal={Neurology},
  year={2018},
  volume={90},
  pages={e22 - e30}
}
Objective To examine neurofilament (Nf) concentrations according to symptom onset and clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS). Methods We measured Nf light chain (NfL) and phosphorylated Nf heavy chain (pNfH) CSF and NfL serum levels in patients with ALS with first symptom onset ≤6 months (n = 54) or >6 months (n = 135) from sampling, and patients with other neurologic diseases, differential diagnoses of a motor neuron disease (MND mimics), and other MND… 

Figures and Tables from this paper

Diagnostic Performance of Neurofilaments in Chinese Patients With Amyotrophic Lateral Sclerosis: A Prospective Study
TLDR
This is the first prospective study to confirm the diagnostic value of Nf for ALS in Chinese patients, and the concentration of pNfH in the CSF was correlated with disease duration.
Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study
TLDR
The role of CSF pNfH as a prognostic biomarker for motor neuron diseases presenting with UMN signs is supported, and a potential power to discriminate between ALS and other UMN syndromes at presentation, and between all of the examined MND and HC is detected.
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
TLDR
Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker and establish a cut-off level for the diagnosis of ALS.
Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study
TLDR
The stable longitudinal trajectory of pNfL supports its use as a marker of drug effect in clinical trials and has excellent diagnostic and prognostic performance for symptomatic patients with ALS.
Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS
TLDR
It is demonstrated that CSF NfL and NfH as well as serum NFL are equally suited for the differential diagnosis of ALS, whereas serum N fH appears to be slightly less potent.
Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature
TLDR
Nfs are considered as promising and useful biomarkers in diagnosis of MND, early patient identification for inclusion in clinical trials, prediction of disease progression, and response to pharmacological intervention, and the validation of their measurement in clinical activity is suggested.
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
TLDR
Especially in ALS, NFL levels are generally stable over time, which, together with their correlation with progression rate, makes NFL an ideal pharmacodynamic biomarker for therapeutic trials and discusses unsolved issues and potential for future developments.
Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis
TLDR
Among all biomarkers, NfL yielded the highest diagnostic performance and was the best predictor of disease progression rate and survival in ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes.
CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression
TLDR
CSF NFL may not be sufficient to distinguish ALS from other central nervous system diseases or peripheral neuropathy, but it predicts ALS severity and progression.
Correlational Analysis of ALS Progression and Serum NfL Measured by Simoa Assay in Chinese Patients
TLDR
The results demonstrated that the level of serum NFL may become a potential biomarker for ALS diagnosis and indicate disease severity and progression and demonstrate diagnostic value in the Chinese ALS population using the ultrasensitive Simoa technology.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
TLDR
Blood and CSF neurofilament levels are linked to the symptomatic phase of ALS and might serve as objective markers of structural damage to the nervous system.
Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
TLDR
This study provides Class II evidence that elevated concentrations of CSF pNfH and NfL can accurately identify patients with ALS and shows an added value as diagnostic biomarkers for ALS, whereas the prognostic value of pNFH andNfL warrants further investigation.
CSF neurofilament protein analysis in the differential diagnosis of ALS
TLDR
The results suggest that, in the clinical work-up of patients suspected of ALS, application of CSF analysis alone is limited but may have potential in combination with other clinical and electrophysiological markers.
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
TLDR
Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients and their value as prognostic markers should be investigated further.
Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS
TLDR
Values in ALS patients are already comparable between most centers, supporting eventual implementation into clinical routine, however, continuous quality control programs will be necessary for inclusion in the diagnostic work-up.
Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF
TLDR
NFL is a main structural protein of axons, and it is suggested that CSF NFL can be used to monitor neurodegeneration in general, but particularly in ALS with involvement of the pyramidal tract.
Axonal damage markers in cerebrospinal fluid are increased in ALS
TLDR
It is proposed that axonal damage markers in CSF may discriminate between subtypes of ALS and that they could be used as markers for therapeutic trials.
Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis
TLDR
Higher pNF-H levels in plasma, serum and CSF showed evidence of association with faster decline in ALSFRS-R and raising the possibility that site of ALS onset (bulbar vs spinal) may influence p NF-H Levels in peripheral blood seems noteworthy but requires confirmation.
Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net
TLDR
Serum NF-L in any ALS disease stage is a promising marker to support diagnosis and predict outcome, while serum PGRN and S100B are only of minor prognostic value.
...
...